Company news
Amarantus Bioscience Holdings, Inc. (OTC:AMBS) news
Amarantus Bioscience Holdings, Inc. news releases on 6ix. Latest, Jan 27, 2016: Amarantus Announces $1M Investment
Press releases — page 4
Amarantus Announces $1M Investment
January 27, 2016
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
January 19, 2016
Amarantus Enters into Letter of Intent to Merge Diagnostics Business Unit into Avant Diagnostics
January 19, 2016
Amarantus to Present at ICV Sonoma Event
January 15, 2016
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
January 11, 2016
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
December 29, 2015
Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
December 22, 2015
Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID
December 16, 2015
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)
December 15, 2015
StockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.
December 14, 2015
Amarantus Retains WallachBeth Capital to Evaluate Strategic Options for MANF Gene Therapy Program
December 10, 2015
Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression
December 8, 2015
Amarantus to Present at ICV Manhattan Event on December 8, 2015
December 7, 2015
Amarantus to Present at LD Micro Main Event on December 3, 2015
December 3, 2015
Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
November 13, 2015
Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease
October 29, 2015
Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs
October 26, 2015
Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
October 22, 2015
Amarantus to Present at BIO Investor Forum 2015
October 19, 2015
Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns
October 14, 2015
Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
October 8, 2015
Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
October 6, 2015
Amarantus to Present at the 2015 Aegis Growth Conference
October 5, 2015
Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases
October 1, 2015
Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible
October 1, 2015
Amarantus Announces an Interactive Live Webcast Presentation at VirtualInvestorConferences.com on October 1, 2015
September 30, 2015
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
September 28, 2015
Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion
September 14, 2015
Amarantus Announces Results of Annual Meeting
September 3, 2015
Amarantus Moves Annual Meeting Date Forward to September 2, 2015
August 26, 2015
Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
August 20, 2015
Amarantus Reports Second Quarter 2015 Financial Results and Business Overview
August 17, 2015
Amarantus Announces Adjournment of Annual Meeting
August 7, 2015
Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID
August 5, 2015
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds
August 3, 2015
Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
July 29, 2015
Amarantus Diagnostics Establishes Strategic Advisory Committee
July 27, 2015
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Associat
July 22, 2015
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
July 20, 2015
Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
July 15, 2015
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
July 13, 2015
OTC Markets Group Welcomes Amarantus BioScience Holdings to OTCQX
July 13, 2015
Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson's Disease and Movement Disorders
June 15, 2015